drug · protein
efruxifermin
Phase 3updated 3mo agoby Akero Therapeutics Inc🔗 ChEMBL
Phase 3community read0 votes
Protein drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying efruxifermin
- phase3A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- phase3A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- phase3A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- phase2A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that